Edwards Lifesciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EW and other ETFs, options, and stocks.

About EW

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. 

CEO
Bernard J. Zovighian
CEOBernard J. Zovighian
Employees
16,000
Employees16,000
Headquarters
Irvine, California
HeadquartersIrvine, California
Founded
1958
Founded1958
Employees
16,000
Employees16,000

EW Key Statistics

Market cap
52.00B
Market cap52.00B
Price-Earnings ratio
52.71
Price-Earnings ratio52.71
Dividend yield
Dividend yield
Average volume
4.28M
Average volume4.28M
High today
$90.36
High today$90.36
Low today
$88.77
Low today$88.77
Open price
$89.49
Open price$89.49
Volume
2.31M
Volume2.31M
52 Week high
$96.29
52 Week high$96.29
52 Week low
$72.30
52 Week low$72.30

Stock Snapshot

With a market cap of 52B, Edwards Lifesciences(EW) trades at $89.72. The stock has a price-to-earnings ratio of 52.71.

On 2026-08-08, Edwards Lifesciences(EW) stock traded between a low of $88.77 and a high of $90.36. Shares are currently priced at $89.72, which is +1.1% above the low and -0.7% below the high.

The Edwards Lifesciences(EW)'s current trading volume is 2.31M, compared to an average daily volume of 4.28M.

In the last year, Edwards Lifesciences(EW) shares hit a 52-week high of $96.29 and a 52-week low of $72.30.

In the last year, Edwards Lifesciences(EW) shares hit a 52-week high of $96.29 and a 52-week low of $72.30.

EW News

Simply Wall St 2d
Upgraded 2026 Sales Outlook for Structural Heart Portfolio Could Be A Game Changer For Edwards Lifesciences

In July 2026, Edwards Lifesciences reported second-quarter 2026 results showing sales of US$1.74 billion and net income of US$241.9 million, while issuing third...

Upgraded 2026 Sales Outlook for Structural Heart Portfolio Could Be A Game Changer For Edwards Lifesciences

Analyst ratings

77%

of 30 ratings
Buy
76.7%
Hold
23.3%
Sell
0%

People also own

Based on the portfolios of people who own EW. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.